Integrated Serum Multiomics Reveal Subtype‐Specific Immune Dysregulation and Sex‐Dimorphic Pathophysiology in Moyamoya Disease
Open Access
- 4 August 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (15)
Abstract
Background: Moyamoya disease (MMD) is a rare cerebrovascular disorder with unknown pathogenesis, partly due to limited access to human cerebral vascular tissue and suitable animal models. Using a large biobank of frozen serum samples, this study aimed to explore molecular signatures of ischemic and hemorrhagic MMD. Methods: Serum from 30 patients with MMD (18 ischemic, 12 hemorrhagic) and 30 matched healthy controls underwent proteomic and metabolomic profiling. Data were analyzed for differential expression, pathway enrichment, and protein–metabolite networks, with adjustment for age, sex, and body mass index. Results: In a separate large Chinese cohort (n=6167), female patients had a higher proportion of hemorrhagic MMD (19.9% versus 16.9%) and a higher prevalence of anterior choroidal artery dilation (15.1% versus 13.2%) than male patients (both P <0.05). At the molecular level, ischemic MMD showed complement C4‐B deficiency and disrupted natural killer cell cytotoxicity; both subtypes shared immunoglobulin perturbations (eg, decreased heavy‐chain variable regions). Sex‐specific alterations included anti–folate‐binding protein, serum amyloid A2, glycolithocholic acid, and estradiol. All omics data are publicly accessible. Conclusions: Integrated serum multiomics defines distinct immune‐related signatures for ischemic and hemorrhagic MMD and reveals sex‐dimorphic molecular pathways. These findings, together with clinical sex differences in disease subtype and vascular anatomy, provide a framework for personalized, sex‐aware management of MMD.Keywords
This publication has 53 references indexed in Scilit:
- Postoperative seizure, stroke, hemorrhage, and cerebral hyperperfusion syndrome rates in adult patients with moyamoya disease undergoing revascularization: a systematic review and proportional meta-analysisNeurosurgical Review, 2026
- Choroid plexus enlargement correlates with cognitive dysfunction and disease progression in Moyamoya diseaseNeurosurgical Review, 2025
- Serum amyloid A augments the atherogenic effects of cholesteryl ester transfer proteinJournal of Lipid Research, 2023
- Serum Metabolome Analysis Identified Amino-Acid Metabolism Associated With Pain in People With Symptomatic Knee Osteoarthritis – A Cross-Sectional StudyThe Journal of Pain, 2023
- Moyamoya disease emerging as an immune-related angiopathyTrends in Molecular Medicine, 2022
- Plasma Trimethylamine N -Oxide, a Gut Microbe–Generated Phosphatidylcholine Metabolite, Is Associated With Atherosclerotic BurdenJACC, 2016
- Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseasesEuropean Journal of Pharmacology, 2006
- Isolation of very low density lipoprotein phospholipids enriched in ethanolamine phospholipids from rats injected with Triton WR 1339Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2005
- Evolution of the Serum Amyloid A (SAA) Protein SuperfamilyGenomics, 1994
- Cerebrovascular "Moyamoya" DiseaseArchives of Neurology, 1969